Claims

1. A medicament comprising an immunoconjugate that binds to FOLR1 for use in treating a cancer that expresses FOLR1 polypeptide, wherein administration of the medicament produces a Cmax of 100-150 μg/mL.

2. The medicament of claim 1, wherein the immunoconjugate is for administration at a dose of about 3 mg/kg to about 6 mg/kg.

3. The medicament of claim 2, wherein the immunoconjugate is for administration at a dose of about 3.0 mg/kg, about 3.3 mg/kg, about 5.0 mg/kg, about 5.5 mg/kg, about 6.0 mg/kg, or about 6.5 mg/kg.

4. The medicament of claim 1, wherein the immunoconjugate is for administration about once every week.

5. The medicament of any one of claims 1-4, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof comprising a light chain CDR1 comprising SEQ ID NO:6, a light chain CDR2 comprising SEQ ID NO:7, a light chain CDR3 comprising SEQ ID NO:8, a heavy chain CDR1 comprising SEQ ID NO:9, a heavy chain CDR2 comprising SEQ ID NO: 10 or 11, and a heavy chain CDR3 comprising SEQ ID NO:12.

6. The medicament of claim 5, wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof comprising a variable light chain comprising SEQ ID NO:5 and a variable heavy chain comprising SEQ ID NO:3.

7. The medicament of claim 6, wherein the immunoconjugate is IMGN853.

8. The medicament of any one of claims 1-7, wherein the immunoconjugate is to be administered intravenously.

9. The medicament of any one of claims 1-8, wherein cancer is selected from the group consisting of ovarian cancer, brain cancer, breast cancer, uterine cancer, endometrial cancer, pancreatic cancer, renal cancer, cancer of the peritoneum, and lung cancer.

10. The medicament of claim 9, wherein the lung cancer is non small cell lung cancer or bronchioloalveolar carcinoma.

11. The medicament of claim 9, wherein the ovarian cancer is epithelial ovarian cancer, platinum resistant ovarian cancer, relapsed ovarian cancer, or refractory ovarian cancer.

12. The medicament of claim 1, wherein the FOLR1 expression levels are measured by immunohistochemistry (IHC).

13. The medicament of any one of claims 1-12, wherein the medicament is for co-administration with a steroid, wherein the steroid is optionally dexamethasone.

14. The medicament of any one of claims 1-13, wherein the administration results in a decrease in tumor size or a decrease in CA125.

WHAT IS CLAIMED IS:

1. The method of claim 16, wherein the lung cancer is non small cell lung cancer or bronchioloalveolar carcinoma.